- Home
- LDI vs VNDA Comparison
LDI vs VNDA Comparison
Compare LDI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDI | VNDA |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 587.6M | 474.0M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LDI | VNDA |
|---|---|---|
| Price | $1.42 | $7.15 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.00 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 1.8M | 1.5M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $17.58 | $21.35 |
| Revenue Next Year | $13.99 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.02 | $3.81 |
| 52 Week High | $5.05 | $9.91 |
Technical Indicators
Market Signals| Indicator | LDI | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.67 | 44.95 |
| Support Level | $1.31 | $7.12 |
| Resistance Level | $1.96 | $8.29 |
| Average True Range (ATR) | 0.08 | 0.33 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 51.59 | 46.72 |
Price Performance
Historical ComparisonAbout LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.